

# Author Index Volume 49 (2016)

The issue number is given in front of the pagination

- Aasly, J.O., see Berge, G. (2) 493–502  
Abdul-Hay, S.O., see Li, H. (1) 129–137  
Abizanda, P., see Salmerón, S. (1) 73–78  
Agostini, S., R. Mancuso, F. Baglio, M. Cabinio, A. Hernis, F.R. Guerini, E. Calabrese, R. Nemni and M. Clerici, Lack of Evidence for a Role of HHV-6 in the Pathogenesis of Alzheimer's Disease (1) 229–235  
Ahdidan, J., C.A. Raji, E.A. DeYoe, J. Mathis, K.Ø. Noe, J. Rimestad, T.K. Kjeldsen, J. Mosegaard, J.T. Becker and O. Lopez, Quantitative Neuroimaging Software for Clinical Assessment of Hippocampal Volumes on MR Imaging (3) 723–732  
Alata, W., see Do, T.M. (2) 287–300  
Alvarez, M.T.B., see Shah, D.J. (2) 317–327  
Ames, D., see Kinsella, G.J. (1) 31–43  
Ames, D., see Zwan, M.D. (4) 1115–1122  
Anand, S., see Banerjee, P. (3) 681–693  
Anand, S., see Shah, D.J. (2) 317–327  
Antonell, A., see Pastor, P. (2) 343–352  
Aparasu, R.R., see Mehta, H.B. (2) 423–432  
Apostolova, L.G., see Madhavan, A. (3) 633–643  
Arancio, O., see Fà, M. (3) 707–721  
Armstrong, N.J., see Wu, H.Z.Y. (3) 755–766  
Arnaldi, D., see Lizio, R. (1) 159–177  
Arroyo-Anlló, E.M., A.T. Boustou, M.-N. Fargeau, B.O. Baz and R. Gil, Self-Consciousness in Patients with Behavioral Variant Frontotemporal Dementia (4) 1021–1029  
Ash, E.L., see Elkana, O. (3) 607–616  
Assam, P.N., see Kandiah, N. (4) 1169–1177  
Auff, E., see Stogmann, E. (4) 1043–1050  
  
Babiloni, C., see Lizio, R. (1) 159–177  
Baglio, F., see Agostini, S. (1) 229–235  
Baiyewu, O., see Kim, S. (4) 991–1003  
Banerjee, P., A. Sahoo, S. Anand, A. Bir and S. Chakrabarti, The Oral Iron Chelator, Deferasirox, Reverses the Age-Dependent Alterations in Iron and Amyloid- $\beta$  Homeostasis in Rat Brain: Implications in the Therapy of Alzheimer's Disease (3) 681–693  
Barandiarán, M., see Pastor, P. (2) 343–352  
Barrado, L.G., E. Coart, H.M.J. Vanderstichele and T. Burzykowski, Transferring Cut-off Values between Assays for Cerebrospinal Fluid Alzheimer's Disease Biomarkers (1) 187–199  
Barrado, L.G., see Rosenberger, A.F.N. (4) 927–943  
Barrett, S.L., see McGuinness, B. (4) 1095–1103  
Başar, E., see Lizio, R. (1) 159–177  
Bayer, T.A., see Savastano, A. (1) 101–110  
Baz, B.O., see Arroyo-Anlló, E.M. (4) 1021–1029  
Beaufils, E., see Bouc, R.L. (4) 1075–1083  
Beauregard, J.-M., see Bergeron, D. (3) 695–705  
Becker, J.T., see Ahdidan, J. (3) 723–732  
Beeri, M.S., see Raizes, M. (3) 589–592  
Bejot, Y., see Jacquin-Piques, A. (3) 671–680  
Bennett, D.A., see Han, S.D. (3) 845–851  
Bennett, J., J. Burns, P. Welch and R. Bothwell, Safety and Tolerability of R(+) Pramipexole in Mild-to-Moderate Alzheimer's Disease (4) 1179–1187  
Benoit, M., see Bensamoun, D. (2) 387–398  
Bensafi, M., see Joussain, P. (2) 433–441  
Bensamoun, D., R. Guignard, A.J. Furst, A. Derreumaux, V. Manera, J. Darcourt, M. Benoit, P.H. Robert, R. David and for the Alzheimer's Disease Neuroimaging Initiative, Associations between Neuropsychiatric Symptoms and Cerebral Amyloid Deposition in Cognitively Impaired Elderly People (2) 387–398  
Berge, G., C. Lauridsen, S.B. Sando, D.J. Holder, I. Møller, J.O. Aasly, G. Bråthen, M.J. Savage and L.R. White, Effect of Tween-20 on Core Biomarkers Measured in Cerebrospinal Fluid from Patients with Alzheimer's Disease, Mild Cognitive Impairment, or Healthy Control Individuals (2) 493–502  
Bergeron, D., J.-M. Beauregard, J. Guimond, M.-P. Fortin, M. Houde, S. Poulin, L. Verret, R.W. Bouchard and R. Laforce Jr., Clinical Impact of a Second FDG-PET in Atypical/Unclear Dementia Syndromes (3) 695–705  
Berr, C., see Bouc, R.L. (4) 1075–1083  
Berr, C., see Gabelle, A. (4) 1135–1141  
Berr, C., see Pimouguet, C. (3) 819–828

- Bertolino, A., see Dukart, J. (4) 1143–1159
- Bertoux, M., L.C. de Souza, C. O'Callaghan, A. Greve, M. Sarazin, B. Dubois and M. Hornberger, Social Cognition Deficits: The Key to Discriminate Behavioral Variant Frontotemporal Dementia from Alzheimer's Disease Regardless of Amnesia? (4) 1065–1074
- Bessy, M., see Jouslain, P. (2) 433–441
- Betzale, V., see Elkana, O. (3) 607–616
- Bir, A., see Banerjee, P. (3) 681–693
- Bjerke, M., S. Kern, K. Blennow, H. Zetterberg, M. Waern, A. Börjesson-Hanson, S. Östling, J. Kern and I. Skoog, Cerebrospinal Fluid Fatty Acid-Binding Protein 3 is Related to Dementia Development in a Population-Based Sample of Older Adult Women Followed for 8 Years (3) 733–741
- Blennow, K., see Bjerke, M. (3) 733–741
- Blennow, K., see Spiegel, J. (1) 93–100
- Boada, M., see Pastor, P. (2) 343–352
- Bonin-Guillaume, S., see Jacquin-Piques, A. (3) 671–680
- Börjesson-Hanson, A., see Bjerke, M. (3) 733–741
- Bothwell, R., see Bennett, J. (4) 1179–1187
- Bouc, R.L., C. Marelli, E. Beaufiles, C. Berr, C. Hommet, J. Touchon, F. Pasquier and V. Deramecourt, Limiting Factors of Brain Donation in Neurodegenerative Diseases: The Example of French Memory Clinics (4) 1075–1083
- Bouchard, R.W., see Bergeron, D. (3) 695–705
- Bourasset, F., see Do, T.M. (2) 287–300
- Bourgeat, P., see Zwan, M.D. (4) 1115–1122
- Bouston, A.T., see Arroyo-Anlló, E.M. (4) 1021–1029
- Boyle, P.A., see Han, S.D. (3) 845–851
- Bragason, D.T., see Einarsdottir, A.B. (1) 79–83
- Brashear, H.R., see Novak, G. (4) 1123–1134
- Bråthen, G., see Berge, G. (2) 493–502
- Brenner, W., see Lange, C. (4) 945–959
- Brewer, G.J., see LeVault, K.R. (2) 301–316
- Brodaty, H., see Wu, H.Z.Y. (3) 755–766
- Broecker-Preuss, M., see Dlugaj, M. (4) 1031–1042
- Broecker-Preuss, M., see Winkler, A. (3) 797–807
- Bruno, G., see Tosto, G. (4) 1085–1093
- Buchert, R., see Lange, C. (4) 945–959
- Buckley, R., see Zwan, M.D. (4) 1115–1122
- Bullido, M.J., see Pastor, P. (2) 343–352
- Burns, J., see Bennett, J. (4) 1179–1187
- Burzykowski, T., see Barrado, L.G. (1) 187–199
- Bussell, C.A., see Gavett, B.E. (2) 531–545
- Butler, T., see Spiegel, J. (1) 93–100
- Butterfield, D.A., see Triplett, J.C. (1) 45–62
- Cabinio, M., see Agostini, S. (1) 229–235
- Caga, J., see Hsieh, S. (3) 875–885
- Cai, J., see Triplett, J.C. (1) 45–62
- Calabrese, E., see Agostini, S. (1) 229–235
- Calero, M., see Pastor, P. (2) 343–352
- Calon, F., see Do, T.M. (2) 287–300
- Cao, J., see Shi, Z. (2) 399–405
- Cao, L., see Shan, Y. (3) 829–844
- Caravaggio, F., see Chung, J.K. (3) 743–754
- Carducci, F., see Lizio, R. (1) 159–177
- Carp, R.I., see Lee, G.-H. (4) 1005–1019
- Carro, E., see Pastor, P. (2) 343–352
- Casañas-Sánchez, V., see Díaz, M. (2) 459–481
- Cavedo, E., see Lizio, R. (1) 159–177
- Cenina, A.R., see Kandiah, N. (4) 1169–1177
- Chakrabarti, S., see Banerjee, P. (3) 681–693
- Chakravarty, M.M., see Chung, J.K. (3) 743–754
- Chakravarty, M.M., see Leh, S.E. (1) 237–249
- Chan, Q.L., X. Xu, M.A. Shaik, S.S.T. Chong, R.J.Y. Hui, C. Li-Hsian Chen and Y. Dong, Clinical Utility of the Informant AD8 as a Dementia Case Finding Instrument in Primary Healthcare (1) 121–127
- Chander, R.J., see Kandiah, N. (4) 1169–1177
- Chen, H., see Mehta, H.B. (2) 423–432
- Chen, S.-D., see Tang, H.-D. (4) 917–925
- Chen, T.-R., see Li, F.-D. (1) 139–147
- Cheong, C.Y., see Kandiah, N. (4) 1169–1177
- Choi, E.-K., see Lee, G.-H. (4) 1005–1019
- Choi, H.-S., see Lee, G.-H. (4) 1005–1019
- Choi, S.H., see Ye, B.S. (2) 483–491
- Choi, S.H., see Yoon, B. (1) 85–91
- Chong, S.S.T., see Chan, Q.L. (1) 121–127
- Chu, D., J. Tan, S. Xie, N. Jin, X. Yin, C.-X. Gong, K. Iqbal and F. Liu, GSK-3 $\beta$  is Dephosphorylated by PP2A in a Leu309 Methylation-Independent Manner (2) 365–375
- Chung, J.K., E. Plitman, S. Nakajima, M.M. Chakravarty, F. Caravaggio, H. Takeuchi, P. Gerretsen, Y. Iwata, R. Patel, B.H. Mulsant, A. Graff-Guerrero and for the Alzheimer's Disease Neuroimaging Initiative, Depressive Symptoms and Small Hippocampal Volume Accelerate the Progression to Dementia from Mild Cognitive Impairment (3) 743–754
- Claassen, J.A.H.R., see van Uden, I.W.M. (3) 863–873
- Clare, L., see Kinsella, G.J. (1) 31–43
- Clarimón, J., see Pastor, P. (2) 343–352
- Clark, C.N., J.M. Nicholas, E. Gordon, H.L. Golden, M.H. Cohen, F.J. Woodward, K. Macpherson, C.F. Slattery, C.J. Mummery, J.M. Schott, J.D. Rohrer

- and J.D. Warren, Altered Sense of Humor in Dementia (1) 111–119
- Clegg, S., see Novak, G. (4) 1123–1134
- Clerici, M., see Agostini, S. (1) 229–235
- Coart, E., see Barrado, L.G. (1) 187–199
- Coart, E., see Rosenberger, A.F.N. (4) 927–943
- Cobell, J., see Shah, D.J. (2) 317–327
- Cohen, M.H., see Clark, C.N. (1) 111–119
- Collins, P., see Novak, G. (4) 1123–1134
- Combarros, O., see Pastor, P. (2) 343–352
- Cordone, S., see Lizio, R. (1) 159–177
- Coto, E., see Pastor, P. (2) 343–352
- Coutu, J.-P., A. Goldblatt, H.D. Rosas, D.H. Salat and the Alzheimer's Disease Neuroimaging Initiative (ADNI), White Matter Changes are Associated with Ventricular Expansion in Aging, Mild Cognitive Impairment, and Alzheimer's Disease (2) 329–342
- Cui, W., see Xie, H. (4) 961–969
- Cui, Y., see Liu, J. (4) 1051–1064
- Da Costa Dias, B., see Pinnock, E.C. (3) 645–657
- Dal-Bianco, P., see Stogmann, E. (4) 1043–1050
- Darcourt, J., see Bensamoun, D. (2) 387–398
- Dartigues, J.-F., see Gabelle, A. (4) 1135–1141
- Dartigues, J.F., see Pimouguet, C. (3) 819–828
- David, R., see Bensamoun, D. (2) 387–398
- Davies, P., see Spiegel, J. (1) 93–100
- de Jong, I.E.M., see Jul, P. (3) 783–795
- de Laat, K.F., see van Uden, I.W.M. (3) 863–873
- de Leeuw, F.-E., see van Uden, I.W.M. (3) 863–873
- de Leon, M.J., see Spiegel, J. (1) 93–100
- De Luca, A., see Tumminelli, G. (1) 27–30
- de Munain, A.L., see Pastor, P. (2) 343–352
- de Pancorbo, M.M., see Pastor, P. (2) 343–352
- De Rosa, S., see Lizio, R. (1) 159–177
- de Souza, L.C., see Bertoux, M. (4) 1065–1074
- Del Percio, C., see Lizio, R. (1) 159–177
- Dell'Agnello, G., see Dubois, B. (3) 617–631
- Delphin-Combe, F., see Joussein, P. (2) 433–441
- den Dunnen, W., see Rüb, U. (4) 905–915
- Deramecourt, V., see Bouc, R.L. (4) 1075–1083
- Derreumaux, A., see Bensamoun, D. (2) 387–398
- DeYoe, E.A., see Ahdidan, J. (3) 723–732
- Di Donato, I., see Tumminelli, G. (1) 27–30
- Di, J., see Novak, G. (4) 1123–1134
- Díaz, M., N. Fabelo, V. Casañas-Sánchez, R. Marin, T. Gómez, D. Quinto-Aleman and J.A. Pérez, Hippocampal Lipid Homeostasis in APP/PS1 Mice is Modulated by a Complex Interplay Between Dietary DHA and Estrogens: Relevance for Alzheimer's Disease (2) 459–481
- Dlugaj, M., A. Winkler, C. Weimar, J. Dürig, M. Broecker-Preuss, N. Dragano, S. Moebus, K.-H. Jöckel, R. Erbel and L. Eisele on behalf of the Heinz Nixdorf Recall Study Investigative Group, Anemia and Mild Cognitive Impairment in the German General Population (4) 1031–1042
- Dlugaj, M., see Winkler, A. (3) 797–807
- Do, T.M., A. Dodacki, W. Alata, F. Calon, S. Nolicic, J.-M. Scherrmann, R. Farinotti and F. Bourasset, Age-Dependent Regulation of the Blood-Brain Barrier Influx/Efflux Equilibrium of Amyloid- $\beta$  Peptide in a Mouse Model of Alzheimer's Disease (3xTg-AD) (2) 287–300
- Dobson, R.J.B., see Voyle, N. (3) 659–669
- Dodacki, A., see Do, T.M. (2) 287–300
- Dols-Icardo, O., see Pastor, P. (2) 343–352
- Dong, Y., see Chan, Q.L. (1) 121–127
- Doody, R.S., see Salmerón, S. (1) 73–78
- Doraiswamy, P.M., see Kim, S. (4) 991–1003
- Doré, V., see Zwan, M.D. (4) 1115–1122
- Dou, F., see Geng, J. (4) 1161–1168
- Dragano, N., see Dlugaj, M. (4) 1031–1042
- Dragano, N., see Winkler, A. (3) 797–807
- Dricot, L., see Pierrot, N. (2) 271–276
- Drubach, D.A., see Madhavan, A. (3) 633–643
- Duan, Y., see Liu, J. (4) 1051–1064
- Dubois, B., A. Padovani, P. Scheltens, A. Rossi and G. Dell'Agnello, Timely Diagnosis for Alzheimer's Disease: A Literature Review on Benefits and Challenges (3) 617–631
- Dubois, B., see Bertoux, M. (4) 1065–1074
- Duffy, J.R., see Madhavan, A. (3) 633–643
- Dukart, J., F. Sambataro, A. Bertolino and for the Alzheimer's Disease Neuroimaging Initiative, Accurate Prediction of Conversion to Alzheimer's Disease using Imaging, Genetic, and Neuropsychological Biomarkers (4) 1143–1159
- Duning, T., see Johnen, A. (3) 593–605
- Dürig, J., see Dlugaj, M. (4) 1031–1042
- Edwards, M., J. Hall, B. Williams, L. Johnson and S. O'Bryant, Molecular Markers of Amnesic Mild Cognitive Impairment among Mexican Americans (1) 221–228
- Einarsdottir, A.B., S.H. Hardarson, J.V. Kristjansdottir, D.T. Bragason, J. Snaedal and E. Stefánsson, Retinal Oximetry Imaging in Alzheimer's Disease (1) 79–83

- Einstein, S., see Novak, G. (4) 1123–1134  
 Eisele, L., see Dlugaj, M. (4) 1031–1042  
 Eisikovits, O.R., see Elkana, O. (3) 607–616  
 Elcoroaristizabal, X., see Pastor, P. (2) 343–352  
 Elkana, O., O.R. Eisikovits, N. Oren, V. Betzale, N. Giladi and E.L. Ash, Sensitivity of Neuropsychological Tests to Identify Cognitive Decline in Highly Educated Elderly Individuals: 12 Months Follow up (3) 607–616  
 Elkana, O., see Raizes, M. (3) 589–592  
 Ellis, K.A., see Zwan, M.D. (4) 1115–1122  
 Elvang, A.B., see Jul, P. (3) 783–795  
 Erbel, R., see Dlugaj, M. (4) 1031–1042  
 Erbel, R., see Winkler, A. (3) 797–807
- Fà, M., H. Zhang, A. Staniszewski, F. Saeed, L.W. Shen, I.T. Schiefer, M.I. Siklos, S. Tapadar, V.A. Litosh, J. Libien, P.A. Petukhov, A.F. Teich, G.R.J. Thatcher and O. Arancio, Novel Selective Calpain 1 Inhibitors as Potential Therapeutics in Alzheimer's Disease (3) 707–721  
 Fabelo, N., see Díaz, M. (2) 459–481  
 Fargeau, M.-N., see Arroyo-Anlló, E.M. (4) 1021–1029  
 Farinotti, R., see Do, T.M. (2) 287–300  
 Federico, A., see Tumminelli, G. (1) 27–30  
 Ferdenzi, C., see Joussain, P. (2) 433–441  
 Fernández-Blázquez, M.Á., see Pastor, P. (2) 343–352  
 Fernández-Sánchez, M., see Salmerón, S. (1) 73–78  
 Ferreira, E., see Pinnock, E.C. (3) 645–657  
 Ferri, R., see Lizio, R. (1) 159–177  
 Flanagan, E., see Hsieh, S. (3) 875–885  
 Flores-Ruano, T., see Salmerón, S. (1) 73–78  
 Foroud, T.M., see Kim, S. (4) 991–1003  
 Fortea, J., see Spiegel, J. (1) 93–100  
 Fortin, M.-P., see Bergeron, D. (3) 695–705  
 Fossati, S., see Spiegel, J. (1) 93–100  
 Fournel, A., see Joussain, P. (2) 433–441  
 Fox, N., see Novak, G. (4) 1123–1134  
 Frank-García, A., see Pastor, P. (2) 343–352  
 Franko, M., see Raizes, M. (3) 589–592  
 Fraser, K.C., J.A. Meltzer and F. Rudzicz, Linguistic Features Identify Alzheimer's Disease in Narrative Speech (2) 407–422  
 Freedberg, D.E., see Lebowhl, B. (1) 179–185  
 Freund, P., see Leh, S.E. (1) 237–249  
 Frings, L., see Lange, C. (4) 945–959  
 Frisoni, G.B., see Lizio, R. (1) 159–177  
 Frölich, L., see Koppara, A. (2) 547–560  
 Frommeyer, J., see Johnen, A. (3) 593–605  
 Fu, J., see Xie, H. (4) 961–969  
 Fu, Y., see Rusznák, Z. (2) 443–457  
 Fuchs, M., see McGuinness, B. (4) 1095–1103  
 Führer-Sakel, D., see Winkler, A. (3) 797–807  
 Fujimoto, H., see Royall, D.R. (2) 561–570  
 Fujimoto, H., see Royall, D.R. (2) 571–579  
 Fukui, K., see Royall, D.R. (2) 561–570  
 Fukui, K., see Royall, D.R. (2) 571–579  
 Furst, A.J., see Bensamoun, D. (2) 387–398
- Gabelle, A., L.-A. Gutierrez, J.-F. Dartigues, K. Ritchie, J. Touchon and C. Berr, Palmomental Reflex a Relevant Sign in Early Alzheimer's Disease Diagnosis? (4) 1135–1141  
 Gao, S., see Kim, S. (4) 991–1003  
 Gao, X., see Tang, H.-D. (4) 917–925  
 Gasse, C., see Nørgaard, A. (1) 211–220  
 Gavett, B.E., S.E. John, A.S. Gurnani, C.A. Bussell and J.L. Saurman, The Role of Alzheimer's and Cerebrovascular Pathology in Mediating the Effects of Age, Race, and Apolipoprotein E Genotype on Dementia Severity in Pathologically-Confirmed Alzheimer's Disease (2) 531–545  
 Geng, J., L. Xia, W. Li, C. Zhao and F. Dou, Cycloheximide Treatment Causes a ZVAD-Sensitive Protease-Dependent Cleavage of Human Tau in Drosophila Cells (4) 1161–1168  
 George, D.R., see Whitehouse, P.J. (1) 21–25  
 Gerretsen, P., see Chung, J.K. (3) 743–754  
 Gertz, H.-J., see Koppara, A. (2) 547–560  
 Gesualdo, L., see Lizio, R. (1) 159–177  
 Ghebremedhin, E., see Rüb, U. (4) 905–915  
 Gietl, A.F., see Leh, S.E. (1) 237–249  
 Gil, R., see Arroyo-Anlló, E.M. (4) 1021–1029  
 Giladi, N., see Elkana, O. (3) 607–616  
 Giroud, M., see Jacquin-Piques, A. (3) 671–680  
 Gleiss, A., see Stogmann, E. (4) 1043–1050  
 Glodzik, L., see Spiegel, J. (1) 93–100  
 Goldblatt, A., see Coutu, J.-P. (2) 329–342  
 Golden, H.L., see Clark, C.N. (1) 111–119  
 Gómez, T., see Díaz, M. (2) 459–481  
 Gong, C.-X., see Chu, D. (2) 365–375  
 Gordon, E., see Clark, C.N. (1) 111–119  
 Gorostidi, A., see Pastor, P. (2) 343–352  
 Graff-Guerrero, A., see Chung, J.K. (3) 743–754  
 Graves, S.W., see Shah, D.J. (2) 317–327  
 Green, P.H.R., see Lebowhl, B. (1) 179–185  
 Gregg, K., see Novak, G. (4) 1123–1134  
 Greve, A., see Bertoux, M. (4) 1065–1074  
 Grundman, M., see Novak, G. (4) 1123–1134  
 Guerini, F.R., see Agostini, S. (1) 229–235  
 Guida, V., see Tumminelli, G. (1) 27–30  
 Guignard, R., see Bensamoun, D. (2) 387–398

- Guimond, J., see Bergeron, D. (3) 695–705  
 Gunter, J.L., see Madhavan, A. (3) 633–643  
 Gureje, O., see Kim, S. (4) 991–1003  
 Gurnani, A.S., see Gavett, B.E. (2) 531–545  
 Gutierrez, L.-A., see Gabelle, A. (4) 1135–1141
- Hall, J., see Edwards, M. (1) 221–228  
 Hall, K.S., see Kim, S. (4) 991–1003  
 Halliday, G.M., see Rusznák, Z. (2) 443–457  
 Hameed, S., see Kandiah, N. (2) 277–285  
 Hampel, H., see Koppara, A. (2) 547–560  
 Han, S.D., P.A. Boyle, B.D. James, L. Yu and D.A. Bennett, Mild Cognitive Impairment and Susceptibility to Scams in Old Age (3) 845–851  
 Han, Y., see Xie, M. (2) 353–363  
 Hanseeuw, B., see Pierrot, N. (2) 271–276  
 Hansen, H.V., see Nørgaard, A. (1) 211–220  
 Hardarson, S.H., see Einarsdottir, A.B. (1) 79–83  
 Hartikainen, S., see Saarelainen, L. (3) 809–818  
 Haußmann, U., see Savastano, A. (1) 101–110  
 Hawes, S.E., see Tosto, G. (4) 1085–1093  
 He, F., see Li, F.-D. (1) 139–147  
 He, M., see Xie, H. (4) 961–969  
 Heinsen, H., see Rüb, U. (4) 905–915  
 Helboe, L., see Jul, P. (3) 783–795  
 Helmer, C., see Pimouguet, C. (3) 819–828  
 Hendrie, H.C., see Kim, S. (4) 991–1003  
 Henn, F., see Koppara, A. (2) 547–560  
 Hernandez, I., see Pastor, P. (2) 343–352  
 Hernis, A., see Agostini, S. (1) 229–235  
 Heuser, I., see Koppara, A. (2) 547–560  
 Hilhorst, R., see Rosenberger, A.F.N. (4) 927–943  
 Hock, C., see Leh, S.E. (1) 237–249  
 Hodges, A., see Voyle, N. (3) 659–669  
 Hodges, J.R., see Hsieh, S. (3) 875–885  
 Hodges, J.R., see Tu, S. (3) 853–861  
 Holder, D.J., see Berge, G. (2) 493–502  
 Hommet, C., see Bouc, R.L. (4) 1075–1083  
 Hong, C.H., see Ye, B.S. (2) 483–491  
 Hoozemans, J.J.M., see Rosenberger, A.F.N. (4) 927–943  
 Hornberger, M., see Bertoux, M. (4) 1065–1074  
 Hornberger, M., see Tu, S. (3) 853–861  
 Hou, M.-M., see Tang, H.-D. (4) 917–925  
 Houde, M., see Bergeron, D. (3) 695–705  
 Hsiao, J.-H.T., see Rusznák, Z. (2) 443–457  
 Hsieh, S., C.E. Leyton, J. Caga, E. Flanagan, C. Kai-zik, C.M. O'Connor, M.C. Kiernan, J.R. Hodges, O. Piguet and E. Mioshi, The Evolution of Care-giver Burden in Frontotemporal Dementia with and without Amyotrophic Lateral Sclerosis (3) 875–885  
 Huang, S., see Xie, H. (4) 961–969  
 Huedo, I., see Salmerón, S. (1) 73–78  
 Hui, R.J.Y., see Chan, Q.L. (1) 121–127  
 Hüll, M., see Koppara, A. (2) 547–560  
 Huo, Y., see Xie, H. (4) 961–969
- Indakoetxea, B., see Pastor, P. (2) 343–352  
 Infante, J., see Pastor, P. (2) 343–352  
 Iqbal, K., see Chu, D. (2) 365–375  
 Ivanoiu, A., see Pierrot, N. (2) 271–276  
 Iwata, Y., see Chung, J.K. (3) 743–754
- Jack Jr, C.R., see Madhavan, A. (3) 633–643  
 Jacquin-Piques, A., G. Sacco, N. Tavassoli, O. Rouaud, Y. Bejot, M. Giroud, P. Robert, B. Vellas and S. Bonin-Guillaume, Psychotropic Drug Prescription in Patients with Dementia: Nursing Home Residents Versus Patients Living at Home (3) 671–680  
 Jahn, H., see Koppara, A. (2) 547–560  
 James, B.D., see Han, S.D. (3) 845–851  
 Jang, B., see Lee, G.-H. (4) 1005–1019  
 Jang, E.Y., see Ye, B.S. (2) 483–491  
 Jensen-Dahm, C., see Nørgaard, A. (1) 211–220  
 Jeon, Y.-C., see Lee, G.-H. (4) 1005–1019  
 Jeong, J.H., see Ye, B.S. (2) 483–491  
 Jessen, F., see Koppara, A. (2) 547–560  
 Jiang, T., see Liu, J. (4) 1051–1064  
 Jin, N., see Chu, D. (2) 365–375  
 Jöckel, K.-H., see Dlugaj, M. (4) 1031–1042  
 Jöckel, K.-H., see Winkler, A. (3) 797–807  
 John, S.E., see Gavett, B.E. (2) 531–545  
 Johnen, A., J. Frommeyer, F. Modes, H. Wiendl, T. Duning and H. Lohmann, Dementia Apraxia Test (DATE): A Brief Tool to Differentiate Behavioral Variant Frontotemporal Dementia from Alzheimer's Dementia Based on Apraxia Profiles (3) 593–605  
 Johnson, J.K., see Särkämö, T. (3) 767–781  
 Johnson, L., see Edwards, M. (1) 221–228  
 Johnson, M.L., see Mehta, H.B. (2) 423–432  
 Johnson, W.E., see Shah, D.J. (2) 317–327  
 Johnston, C., see Voyle, N. (3) 659–669  
 Johnston, J.A., see McGuinness, B. (4) 1095–1103  
 Josephs, K.A., see Madhavan, A. (3) 633–643  
 Joussein, P., M. Bessy, A. Fournel, C. Ferdenzi, C. Rouby, F. Delphin-Combe, P. Krolak-Salmon and M. Bensafi, Altered Affective Evaluations of Smells in Alzheimer's Disease (2) 433–441

- Jovanovic, K., see Pinnock, E.C. (3) 645–657
- Jul, P., C. Volbracht, I.E.M. de Jong, L. Helboe, A.B. Elvang and J.T. Pedersen, Hyperactivity with Agitative-Like Behavior in a Mouse Tauopathy Model (3) 783–795
- Kaddurah-Daouk, R., see Kim, S. (4) 991–1003
- Kaizik, C., see Hsieh, S. (3) 875–885
- Kälin, A.M., see Leh, S.E. (1) 237–249
- Kandiah, N., R.J. Chander, X. Lin, A. Ng, Y.Y. Poh, C.Y. Cheong, A.R. Cenina and P.N. Assam, Cognitive Impairment after Mild Stroke: Development and Validation of the SIGNAL<sub>2</sub> Risk Score (4) 1169–1177
- Kandiah, N., V. Wang, X. Lin, M.M. Nyu, L. Lim, A. Ng, S. Hameed and H.L. Wee, Cost Related to Dementia in the Young and the Impact of Etiological Subtype on Cost (2) 277–285
- Kantarci, K., see Madhavan, A. (3) 633–643
- Kato, Y., see Royall, D.R. (2) 561–570
- Kato, Y., see Royall, D.R. (2) 571–579
- Kauwe, J.S.K., see Shah, D.J. (2) 317–327
- Keohane, A., see Voyle, N. (3) 659–669
- Kern, J., see Bjerke, M. (3) 733–741
- Kern, S., see Bjerke, M. (3) 733–741
- Kessels, R.P.C., see van Uden, I.W.M. (3) 863–873
- Khondoker, M., see Sattlecker, M. (4) 1105–1114
- Kiddle, S., see Voyle, N. (3) 659–669
- Kiernan, M.C., see Hsieh, S. (3) 875–885
- Kim, E.-J., see Ye, B.S. (2) 483–491
- Kim, H.-J., see Lee, G.-H. (4) 1005–1019
- Kim, H.J., see Ye, B.S. (2) 483–491
- Kim, S., K. Nho, V.K. Ramanan, D. Lai, T.M. Foroud, K. Lane, J.R. Murrell, S. Gao, K.S. Hall, F.W. Unverzagt, O. Baiyewu, A. Ogunniyi, O. Gureje, M.A. Kling, P.M. Doraiswamy, R. Kaddurah-Daouk, H.C. Hendrie and A.J. Saykin, Genetic Influences on Plasma Homocysteine Levels in African Americans and Yoruba Nigerians (4) 991–1003
- Kim, S.Y., see Ye, B.S. (2) 483–491
- Kim, W.S., see Rusznák, Z. (2) 443–457
- Kim, Y.K., see Yoo, Y. (2) 377–386
- Kim, Y.-S., see Lee, G.-H. (4) 1005–1019
- King, J., see Shah, D.J. (2) 317–327
- Kinsella, G.J., D. Ames, E. Storey, B. Ong, K.E. Pike, M.M. Saling, L. Clare, E. Mullaly and E. Rand, Strategies for Improving Memory: A Randomized Trial of Memory Groups for Older People, Including those with Mild Cognitive Impairment (1) 31–43
- Kitagawa, K., see Miwa, K. (2) 503–513
- Kjeldsen, T.K., see Ahdidan, J. (3) 723–732
- Klafki, H., see Savastano, A. (1) 101–110
- Klein, J.B., see Triplett, J.C. (1) 45–62
- Kleineidam, L., see Koppara, A. (2) 547–560
- Kling, M.A., see Kim, S. (4) 991–1003
- Kłoszewska, I., see Sattlecker, M. (4) 1105–1114
- Kloszewska, I., see Voyle, N. (3) 659–669
- Klug, S., see Stogmann, E. (4) 1043–1050
- Knackmuss, S., see Pinnock, E.C. (3) 645–657
- Kollias, S., see Leh, S.E. (1) 237–249
- Koponen, M., see Saarelainen, L. (3) 809–818
- Koppara, A., S. Wolfsgruber, L. Kleineidam, K. Schmidtke, L. Frölich, A. Kurz, S. Schulz, H. Hampel, I. Heuser, O. Peters, F.M. Reischies, H. Jahn, C. Luckhaus, M. Hüll, H.-J. Gertz, J. Schröder, J. Pantel, O. Rienhoff, E. Rütther, F. Henn, J. Wiltfang, W. Maier, F. Jessen, J. Kornhuber and M. Wagner, The Latent Dementia Phenotype  $\delta$  is Associated with Cerebrospinal Fluid Biomarkers of Alzheimer's Disease and Predicts Conversion to Dementia in Subjects with Mild Cognitive Impairment (2) 547–560
- Korf, H.-W., see Rüb, U. (4) 905–915
- Kornhuber, J., see Koppara, A. (2) 547–560
- Koski, L., see Xie, H. (4) 961–969
- Koumi, H., see Royall, D.R. (2) 561–570
- Koumi, H., see Royall, D.R. (2) 571–579
- Kristjansdottir, J.V., see Einarsdottir, A.B. (1) 79–83
- Krolak-Salmon, P., see Jousain, P. (2) 433–441
- Kulisevsky, J., see Pastor, P. (2) 343–352
- Kurki, M., see Särkämö, T. (3) 767–781
- Kurz, A., see Koppara, A. (2) 547–560
- Laforce Jr., R., see Bergeron, D. (3) 695–705
- Lai, D., see Kim, S. (4) 991–1003
- Laitinen, S., see Särkämö, T. (3) 767–781
- Lane, K., see Kim, S. (4) 991–1003
- Lange, C., P. Suppa, L. Frings, W. Brenner, L. Spies, R. Buchert and for the Alzheimer's Disease Neuroimaging Initiative, Optimization of Statistical Single Subject Analysis of Brain FDG PET for the Prognosis of Mild Cognitive Impairment-to- Alzheimer's Disease Conversion (4) 945–959
- Lauridsen, C., see Berge, G. (2) 493–502
- Lebwohl, B., J.A. Luchsinger, D.E. Freedberg, P.H.R. Green and J.F. Ludvigsson, Risk of Dementia in Patients with Celiac Disease: A Population-Based Cohort Study (1) 179–185
- Lee, G.-H., B. Jang, H.-S. Choi, H.-J. Kim, J.-H. Park, Y.-C. Jeon, R.I. Carp, Y.-S. Kim and E.-K. Choi, Upregulation of Connexin 43 Expression

- Via C-Jun N-Terminal Kinase Signaling in Prion Disease (4) 1005–1019
- Lee, J.-H., see Ye, B.S. (2) 483–491
- Lee, J.-H., see Yoo, Y. (2) 377–386
- Lee, J.-Y., see Yoo, Y. (2) 377–386
- Lee, S.E., see Pastor, P. (2) 343–352
- Lee, Y., see Ye, B.S. (2) 483–491
- Leffondré, K., see Pimouguet, C. (3) 819–828
- Le-Goff, M., see Pimouguet, C. (3) 819–828
- Leh, S.E., A.M. Kälin, C. Schroeder, M.T.M. Park, M.M. Chakravarty, P. Freund, A.F. Gietl, F. Riese, S. Kollias, C. Hock and L. Michels, Volumetric and Shape Analysis of the Thalamus and Striatum in Amnesic Mild Cognitive Impairment (1) 237–249
- Lehrner, J., see Stogmann, E. (4) 1043–1050
- Leissring, M.A., see Li, H. (1) 129–137
- Lennarz, M., see Pastor, P. (2) 343–352
- LeVault, K.R., S.A. Tischkau and G.J. Brewer, Circadian Disruption Reveals a Correlation of an Oxidative GSH/GSSG Redox Shift with Learning and Impaired Memory in an Alzheimer's Disease Mouse Model (2) 301–316
- Leyton, C.E., see Hsieh, S. (3) 875–885
- Leyton, C.E., see Tu, S. (3) 853–861
- Lhommel, R., see Pierrot, N. (2) 271–276
- Li, C., see Shi, Z. (2) 399–405
- Li, F.-D., F. He, T.-R. Chen, Y.-Y. Xiao, S.-T. Lin, W. Shen, X.-Y. Wang, Y.-J. Zhai, X.-P. Shang and J.-F. Lin, Reproductive History and Risk of Cognitive Impairment in Elderly Women: A Cross-Sectional Study in Eastern China (1) 139–147
- Li, H., H. Zhu, M. Wallack, M. Mwamburi, S.O. Abdul-Hay, M.A. Leissring and W.Q. Qiu, Age and Its Association with Low Insulin and High Amyloid- $\beta$  Peptides in Blood (1) 129–137
- Li, K., see Liu, J. (4) 1051–1064
- Li, W., see Geng, J. (4) 1161–1168
- Li, Y., see Spiegel, J. (1) 93–100
- Li, Y., see Xie, H. (4) 961–969
- Liang, L., see Tang, H.-D. (4) 917–925
- Liao, X., see Xie, M. (2) 353–363
- Libien, J., see Fà, M. (3) 707–721
- Li-Hsian Chen, C., see Chan, Q.L. (1) 121–127
- Lim, L., see Kandiah, N. (2) 277–285
- Lin, J.-F., see Li, F.-D. (1) 139–147
- Lin, S.-T., see Li, F.-D. (1) 139–147
- Lin, X., see Kandiah, N. (2) 277–285
- Lin, X., see Kandiah, N. (4) 1169–1177
- Litosh, V.A., see Fà, M. (3) 707–721
- Little, M., see Pinnock, E.C. (3) 645–657
- Liu, B., see Liu, J. (4) 1051–1064
- Liu, E., see Novak, G. (4) 1123–1134
- Liu, F., see Chu, D. (2) 365–375
- Liu, G., J.G. Weinger, Z.-L. Lu, F. Xue and S. Sadeghpour, Efficacy and Safety of MMFS-01, a Synapse Density Enhancer, for Treating Cognitive Impairment in Older Adults: A Randomized, Double-Blind, Placebo-Controlled Trial (4) 971–990
- Liu, G., see Sun, X. (1) 63–72
- Liu, J., X. Zhang, C. Yu, Y. Duan, J. Zhuo, Y. Cui, B. Liu, K. Li, T. Jiang and Y. Liu, Impaired Parahippocampus Connectivity in Mild Cognitive Impairment and Alzheimer's Disease (4) 1051–1064
- Liu, R., see Pan, Y. (1) 1–12
- Liu, Y., see Liu, J. (4) 1051–1064
- Liu, Y.-S., see Shan, Y. (3) 829–844
- Lizio, R., C. Del Percio, N. Marzano, A. Soricelli, G.G. Yener, E. Başar, C. Mundi, S. De Rosa, A.I. Triggiani, R. Ferri, D. Arnaldi, F.M. Nobili, S. Cordone, S. Lopez, F. Carducci, G. Santi, L. Gesualdo, P.M. Rossini, E. Cavedo, M. Mauri, G.B. Frisoni and C. Babiloni, Neurophysiological Assessment of Alzheimer's Disease Individuals by a Single Electroencephalographic Marker (1) 159–177
- Lleó, A., see Pastor, P. (2) 343–352
- Lohmann, H., see Johnen, A. (3) 593–605
- Lopez, O., see Ahdidan, J. (3) 723–732
- Lopez, S., see Lizio, R. (1) 159–177
- López-Utiel, M., see Salmerón, S. (1) 73–78
- Lorenzo, E., see Pastor, P. (2) 343–352
- Lovestone, S., see Sattlecker, M. (4) 1105–1114
- Lovestone, S., see Voyle, N. (3) 659–669
- Lowe, V.J., see Madhavan, A. (3) 633–643
- Lu, Y., see Novak, G. (4) 1123–1134
- Lu, Z.-L., see Liu, G. (4) 971–990
- Luchsinger, J.A., see Lebowitz, B. (1) 179–185
- Luckhaus, C., see Koppa, A. (2) 547–560
- Ludvigsson, J.F., see Lebowitz, B. (1) 179–185
- Lunnon, K., see Voyle, N. (3) 659–669
- Ma, J.-F., see Tang, H.-D. (4) 917–925
- Ma, R., see Sun, X. (1) 63–72
- Macaulay, S.L., see Zwan, M.D. (4) 1115–1122
- Machulda, M.M., see Madhavan, A. (3) 633–643
- Macpherson, K., see Clark, C.N. (1) 111–119
- Madhavan, A., C.G. Schwarz, J.R. Duffy, E.A. Strand, M.M. Machulda, D.A. Drubach, K. Kantarci, S.A. Przybelski, R.I. Reid, M.L. Senjem, J.L. Gunter, L.G. Apostolova, V.J. Lowe, R.C. Petersen, C.R. Jack Jr, K.A. Josephs and J.L. Whitwell, Characterizing White Matter Tract Degeneration in Syn-

- dromic Variants of Alzheimer's Disease: A Diffusion Tensor Imaging Study (3) 633–643
- Maier, W., see Koppara, A. (2) 547–560
- Maier, W., see Pastor, P. (2) 343–352
- Mäkelä, M., A. Paetau, T. Polvikoski, L. Myllykangas and M. Tanskanen, Capillary Amyloid- $\beta$  Protein Deposition in a Population-Based Study (Vantaa 85+) (1) 149–157
- Maloteaux, J.-M., see Pierrot, N. (2) 271–276
- Mancuso, R., see Agostini, S. (1) 229–235
- Manera, V., see Bensamoun, D. (2) 387–398
- Marelli, C., see Bouc, R.L. (4) 1075–1083
- Margison, L., see Zwan, M.D. (4) 1115–1122
- Marin, R., see Díaz, M. (2) 459–481
- Martins, R., see Zwan, M.D. (4) 1115–1122
- Marzano, N., see Lizio, R. (1) 159–177
- Masters, C.L., see Zwan, M.D. (4) 1115–1122
- Mather, K., see Wu, H.Z.Y. (3) 755–766
- Mathis, J., see Ahdidan, J. (3) 723–732
- Matsuoka, T., see Royall, D.R. (2) 561–570
- Matsuoka, T., see Royall, D.R. (2) 571–579
- Mauri, M., see Lizio, R. (1) 159–177
- Mayeux, R., see Tosto, G. (4) 1085–1093
- McGuinness, B., M. Fuchs, S.L. Barrett, A.P. Passmore and J.A. Johnston, Platelet Membrane  $\beta$ -Secretase Activity in Mild Cognitive Impairment and Conversion to Dementia: a Longitudinal Study (4) 1095–1103
- Mearow, K.M., see Nafar, F. (1) 251–263
- Mecocci, P., see Sattler, M. (4) 1105–1114
- Mecocci, P., see Voyle, N. (3) 659–669
- Mehta, H.B., V. Mehta, C.-L. Tsai, H. Chen, R.R. Aparasu and M.L. Johnson, Development and Validation of the RxDx-Dementia Risk Index to Predict Dementia in Patients with Type 2 Diabetes and Hypertension (2) 423–432
- Mehta, V., see Mehta, H.B. (2) 423–432
- Meltzer, J.A., see Fraser, K.C. (2) 407–422
- Michels, L., see Leh, S.E. (1) 237–249
- Mimura, M., see Royall, D.R. (2) 561–570
- Mimura, M., see Royall, D.R. (2) 571–579
- Mioshi, E., see Hsieh, S. (3) 875–885
- Miwa, K., M. Tanaka, S. Okazaki, Y. Yagita, M. Saka-guchi, H. Mochizuki and K. Kitagawa, Increased Total Homocysteine Levels Predict the Risk of Incident Dementia Independent of Cerebral Small-Vessel Diseases and Vascular Risk Factors (2) 503–513
- Mochizuki, H., see Miwa, K. (2) 503–513
- Modes, F., see Johnen, A. (3) 593–605
- Moebus, S., see Dlugaj, M. (4) 1031–1042
- Moebus, S., see Winkler, A. (3) 797–807
- Møller, I., see Berge, G. (2) 493–502
- Monsell, S.E., see Tosto, G. (4) 1085–1093
- Moreno, F., see Pastor, P. (2) 343–352
- Mosegaard, J., see Ahdidan, J. (3) 723–732
- Moser, D., see Stogmann, E. (4) 1043–1050
- Mullaly, E., see Kinsella, G.J. (1) 31–43
- Muller, P., see Savastano, A. (1) 101–110
- Mulsant, B.H., see Chung, J.K. (3) 743–754
- Mummery, C.J., see Clark, C.N. (1) 111–119
- Mundi, C., see Lizio, R. (1) 159–177
- Murrell, J.R., see Kim, S. (4) 991–1003
- Mwamburi, M., see Li, H. (1) 129–137
- Myllykangas, L., see Mäkelä, M. (1) 149–157
- Na, D.L., see Ye, B.S. (2) 483–491
- Na, H.R., see Ye, B.S. (2) 483–491
- Nafar, F., J.B. Williams and K.M. Mearow, Astrocytes Release HspB1 in Response to Amyloid- $\beta$  Exposure *in vitro* (1) 251–263
- Naji, F., see Rosenberger, A.F.N. (4) 927–943
- Nakaaki, S., see Royall, D.R. (2) 561–570
- Nakaaki, S., see Royall, D.R. (2) 571–579
- Nakajima, S., see Chung, J.K. (3) 743–754
- Nakamura, K., see Royall, D.R. (2) 561–570
- Nakamura, K., see Royall, D.R. (2) 571–579
- Narumoto, J., see Royall, D.R. (2) 561–570
- Narumoto, J., see Royall, D.R. (2) 571–579
- Nemni, R., see Agostini, S. (1) 229–235
- Newhouse, S., see Voyle, N. (3) 659–669
- Ng, A., see Kandiah, N. (2) 277–285
- Ng, A., see Kandiah, N. (4) 1169–1177
- Nho, K., see Kim, S. (4) 991–1003
- Nicholas, J.M., see Clark, C.N. (1) 111–119
- Nicolic, S., see Do, T.M. (2) 287–300
- Nielsen, C., see Novak, G. (4) 1123–1134
- Nobili, F.M., see Lizio, R. (1) 159–177
- Noe, K.Ø., see Ahdidan, J. (3) 723–732
- Noguerón, A., see Salmerón, S. (1) 73–78
- Nørgaard, A., C. Jensen-Dahm, C. Gasse, H.V. Hansen and G. Waldemar, Time Trends in Antipsychotic Drug Use in Patients with Dementia: A Nationwide Study (1) 211–220
- Norris, D.G., see van Uden, I.W.M. (3) 863–873
- Novak, G., N. Fox, S. Clegg, C. Nielsen, S. Einstein, Y. Lu, I.C. Tudor, K. Gregg, J. Di, P. Collins, B.T. Wyman, E. Yuen, M. Grundman, H.R. Brashear



- and E. Liu, Changes in Brain Volume with Bapineuzumab in Mild to Moderate Alzheimer's Disease (4) 1123–1134
- Numminen, A., see Särkämö, T. (3) 767–781
- Nyu, M.M., see Kandiah, N. (2) 277–285
- O'Bryant, S., see Edwards, M. (1) 221–228
- O'Callaghan, C., see Bertoux, M. (4) 1065–1074
- O'Connor, C.M., see Hsieh, S. (3) 875–885
- O'Leary, V.B., see Ovsepian, S.V. (1) 13–19
- Oberstein, T.J., see Savastano, A. (1) 101–110
- Octave, J.-N., see Pierrot, N. (2) 271–276
- Ogawa, M., see Royall, D.R. (2) 561–570
- Ogawa, M., see Royall, D.R. (2) 571–579
- Ogunniyi, A., see Kim, S. (4) 991–1003
- Okamura, A., see Royall, D.R. (2) 561–570
- Okamura, A., see Royall, D.R. (2) 571–579
- Okazaki, S., see Miwa, K. (2) 503–513
- Ong, B., see Kinsella, G.J. (1) 31–43
- Ong, K.L., see Wu, H.Z.Y. (3) 755–766
- Oren, N., see Elkana, O. (3) 607–616
- Ortega-Cubero, S., see Pastor, P. (2) 343–352
- Osorio, R.S., see Spiegel, J. (1) 93–100
- Östling, S., see Bjerke, M. (3) 733–741
- Ovsepian, S.V. and V.B. O'Leary, Neuronal Activity and Amyloid Plaque Pathology: An Update (1) 13–19
- Padovani, A., see Dubois, B. (3) 617–631
- Paetau, A., see Mäkelä, M. (1) 149–157
- Palmer, R.F. and D.R. Royall, Future Dementia Severity is Almost Entirely Explained by the Latent Variable  $\delta$ 's Intercept and Slope (2) 521–529
- Palmer, R.F., see Royall, D.R. (2) 561–570
- Palmer, R.F., see Royall, D.R. (2) 571–579
- Pan, B., see Pan, Y. (1) 1–12
- Pan, Y., R. Liu, E. Terpstra, Y. Wang, F. Qiao, J. Wang, Y. Tong and B. Pan, Dysregulation and Diagnostic Potential of microRNA in Alzheimer's Disease (1) 1–12
- Pantel, J., see Koppara, A. (2) 547–560
- Park, H.-K., see Yoon, B. (1) 85–91
- Park, J.-H., see Lee, G.-H. (4) 1005–1019
- Park, M.T.M., see Leh, S.E. (1) 237–249
- Park, S., see Yoo, Y. (2) 377–386
- Park, S.A., see Ye, B.S. (2) 483–491
- Park, S.A., see Yoon, B. (1) 85–91
- Pasquier, F., see Bouc, R.L. (4) 1075–1083
- Passmore, A.P., see McGuinness, B. (4) 1095–1103
- Pastor, M.A., see Pastor, P. (2) 343–352
- Pastor, P., F. Moreno, J. Clarimón, A. Ruiz, O. Combarros, M. Calero, A.L. de Munain, M.J. Bullido, M.M. de Pancorbo, E. Carro, A. Antonell, E. Coto, S. Ortega-Cubero, I. Hernandez, L. Tárraga, M. Boada, A. Lleó, O. Dols-Icardo, J. Kulisevsky, J.L. Vázquez-Higuera, J. Infante, A. Rábano, M.Á. Fernández-Blázquez, M. Valentí, B. Indakoetxea, M. Barandiarán, A. Gorostidi, A. Frank-García, I. Sastre, E. Lorenzo, M.A. Pastor, X. Elcoroaristizabal, M. Lennarz, W. Maier, A. Ramírez, M. Serrano-Ríos, S.E. Lee, P. Sánchez-Juan and on behalf of The Dementia Genetic Spanish Consortium (DEGESCO), *MAPT* H1 Haplotype is Associated with Late-Onset Alzheimer's Disease Risk in *APOE*  $\epsilon$ 4 Noncarriers: Results from the Dementia Genetics Spanish Consortium (2) 343–352
- Patel, R., see Chung, J.K. (3) 743–754
- Paxinos, G., see Rusznák, Z. (2) 443–457
- Pedersen, J.T., see Jul, P. (3) 783–795
- Penny, C., see Pinnock, E.C. (3) 645–657
- Pérès, K., see Pimouguet, C. (3) 819–828
- Pérez, J.A., see Díaz, M. (2) 459–481
- Peters, O., see Koppara, A. (2) 547–560
- Petersen, R.C., see Madhavan, A. (3) 633–643
- Petukhov, P.A., see Fà, M. (3) 707–721
- Pierrot, N., R. Lhommel, L. Quenon, B. Hanseeuw, L. Dricot, C. Sindic, J.-M. Maloteaux, J.-N. Octave and A. Ivanoiu, Targretin Improves Cognitive and Biological Markers in a Patient with Alzheimer's Disease (2) 271–276
- Piguet, O., see Hsieh, S. (3) 875–885
- Piguet, O., see Tu, S. (3) 853–861
- Pike, K.E., see Kinsella, G.J. (1) 31–43
- Pimouguet, C., M. Le-Goff, D. Rizzuto, C. Berr, K. Lefondré, K. Pérès, J.F. Dartigues and C. Helmer, Effect of Early Referral to Specialist in Dementia on Institutionalization and Functional Decline: Findings from a Population-Based Study (3) 819–828
- Pinnock, E.C., K. Jovanovic, M.G. Pinto, E. Ferreira, B. Da Costa Dias, C. Penny, S. Knackmuss, U. Reusch, M. Little, H.M. Schatzl and S.F.T. Weiss, LRP/LR Antibody Mediated Rescuing of Amyloid- $\beta$ -Induced Cytotoxicity is Dependent on PrP<sup>c</sup> in Alzheimer's Disease (3) 645–657
- Pinto, M.G., see Pinnock, E.C. (3) 645–657
- Pirraglia, E., see Spiegel, J. (1) 93–100
- Plitman, E., see Chung, J.K. (3) 743–754
- Poh, Y.Y., see Kandiah, N. (4) 1169–1177

- Polvikoski, T., see Mäkelä, M. (1) 149–157
- Poulin, S., see Bergeron, D. (3) 695–705
- Proitsi, P., see Sattlecker, M. (4) 1105–1114
- Przybelski, S.A., see Madhavan, A. (3) 633–643
- Pusswald, G., see Stogmann, E. (4) 1043–1050
- Qiao, F., see Pan, Y. (1) 1–12
- Qiao, Y., see Tang, H.-D. (4) 917–925
- Qiu, W.Q., see Li, H. (1) 129–137
- Quenon, L., see Pierrot, N. (2) 271–276
- Quinto-Aleman, D., see Díaz, M. (2) 459–481
- Rábano, A., see Pastor, P. (2) 343–352
- Raizes, M., O. Elkana, M. Franko, R.R. Springer, S. Segev and M.S. Beeri, Higher Fasting Plasma Glucose Levels, within the Normal Range, are Associated with Decreased Processing Speed in High Functioning Young Elderly (3) 589–592
- Raji, C.A., see Ahdidan, J. (3) 723–732
- Ramanan, V.K., see Kim, S. (4) 991–1003
- Rámirez, A., see Pastor, P. (2) 343–352
- Rand, E., see Kinsella, G.J. (1) 31–43
- Randall, C., see Spiegel, J. (1) 93–100
- Rantanen, P., see Särkämö, T. (3) 767–781
- Reid, R.I., see Madhavan, A. (3) 633–643
- Reischies, F.M., see Koppara, A. (2) 547–560
- Rembach, A., see Zwan, M.D. (4) 1115–1122
- Reusch, U., see Pinnock, E.C. (3) 645–657
- Rienhoff, O., see Koppara, A. (2) 547–560
- Riese, F., see Leh, S.E. (1) 237–249
- Rimestad, J., see Ahdidan, J. (3) 723–732
- Ritchie, K., see Gabelle, A. (4) 1135–1141
- Rizzuto, D., see Pimouguet, C. (3) 819–828
- Robert, P., see Jacquin-Piques, A. (3) 671–680
- Robert, P.H., see Bensamoun, D. (2) 387–398
- Rohlfing, F., see Shah, D.J. (2) 317–327
- Rohrer, J.D., see Clark, C.N. (1) 111–119
- Rosas, H.D., see Coutu, J.-P. (2) 329–342
- Rosenberger, A.F.N., R. Hilhorst, E. Coart, L.G. Barrado, F. Naji, A.J.M. Rozemuller, W.M. van der Flier, P. Scheltens, J.J.M. Hoozemans and S.M. van der Vies, Protein Kinase Activity Decreases with Higher Braak Stages of Alzheimer's Disease Pathology (4) 927–943
- Rossi, A., see Dubois, B. (3) 617–631
- Rossini, P.M., see Lizio, R. (1) 159–177
- Rouaud, O., see Jacquin-Piques, A. (3) 671–680
- Rouby, C., see Jousain, P. (2) 433–441
- Rowe, C.C., see Zwan, M.D. (4) 1115–1122
- Royall, D.R., R.F. Palmer, T. Matsuoka, Y. Kato, S. Taniguchi, M. Ogawa, H. Fujimoto, A. Okamura, K. Shibata, K. Nakamura, S. Nakaaki, H. Koumi, M. Mimura, K. Fukui and J. Narumoto,  $\delta$  Scores are Exportable Across Cultural and Linguistic Boundaries (2) 561–570
- Royall, D.R., R.F. Palmer, T. Matsuoka, Y. Kato, S. Taniguchi, M. Ogawa, H. Fujimoto, A. Okamura, K. Shibata, K. Nakamura, S. Nakaaki, H. Koumi, M. Mimura, K. Fukui and J. Narumoto, Greater than the Sum of Its Parts:  $\delta$  can be Constructed from Item Level Data (2) 571–579
- Royall, D.R., see Palmer, R.F. (2) 521–529
- Royall, D.R., Welcome Back to Your Future: The Assessment of Dementia by the Latent Variable “ $\delta$ ” (2) 515–519
- Rozemuller, A.J.M., see Rosenberger, A.F.N. (4) 927–943
- Rüb, U., K. Stratmann, H. Heinsen, D.D. Turco, E. Ghebremedhin, K. Seidel, W. den Dunnen and H.-W. Korf, Hierarchical Distribution of the Tau Cytoskeletal Pathology in the Thalamus of Alzheimer's Disease Patients (4) 905–915
- Rudzicz, F., see Fraser, K.C. (2) 407–422
- Rufa, A., see Tumminelli, G. (1) 27–30
- Ruiz, A., see Pastor, P. (2) 343–352
- Rusznák, Z., W.S. Kim, J.-H.T. Hsiao, G.M. Halliday, G. Paxinos and Y. Fu, Early *in vivo* Effects of the Human Mutant Amyloid- $\beta$  Protein Precursor (hA $\beta$ PPSwInd) on the Mouse Olfactory Bulb (2) 443–457
- Rüther, E., see Koppara, A. (2) 547–560
- Rutten-Jacobs, L.C.A., see van Uden, I.W.M. (3) 863–873
- Saarelainen, L., H. Taipale, M. Koponen, A. Tanskanen, A.-M. Tolppanen, J. Tiihonen and S. Hartikainen, The Incidence of Benzodiazepine and Related Drug Use in Persons with and without Alzheimer's Disease (3) 809–818
- Sacco, G., see Jacquin-Piques, A. (3) 671–680
- Sachdev, P., see Wu, H.Z.Y. (3) 755–766
- Sadeghpour, S., see Liu, G. (4) 971–990
- Saeed, F., see Fà, M. (3) 707–721
- Sahoo, A., see Banerjee, P. (3) 681–693
- Saint Louis, L.A., see Spiegel, J. (1) 93–100
- Sakaguchi, M., see Miwa, K. (2) 503–513
- Salat, D.H., see Coutu, J.-P. (2) 329–342
- Saling, M.M., see Kinsella, G.J. (1) 31–43
- Salmerón, S., I. Huedo, M. López-Utiel, I. Soler-Moratalla, T. Flores-Ruano, M. Fernández-Sánchez, A. Noguerón, R.S. Doody and P. Abizanda, Validation of the Spanish Version of the Baylor Profound Mental Status Examination (1) 73–78
- Salvado, O., see Zwan, M.D. (4) 1115–1122

- Sambataro, F., see Dukart, J. (4) 1143–1159
- Sánchez-Juan, P., see Pastor, P. (2) 343–352
- Sando, S.B., see Berge, G. (2) 493–502
- Santi, G., see Lizio, R. (1) 159–177
- Sarazin, M., see Bertoux, M. (4) 1065–1074
- Särkämö, T., S. Laitinen, A. Numminen, M. Kurki, J.K. Johnson and P. Rantanen, Clinical and Demographic Factors Associated with the Cognitive and Emotional Efficacy of Regular Musical Activities in Dementia (3) 767–781
- Sastre, I., see Pastor, P. (2) 343–352
- Sattlecker, M., M. Khondoker, P. Proitsi, S. Williams, H. Soininen, I. Kłoszewska, P. Mecocci, M. Tsolaki, B. Vellas and S. Lovestone on behalf of the AddNeuroMed Consortium and Richard JB Dobson, Longitudinal Protein Changes in Blood Plasma Associated with the Rate of Cognitive Decline in Alzheimer's Disease (4) 1105–1114
- Saurman, J.L., see Gavett, B.E. (2) 531–545
- Savage, M.J., see Berge, G. (2) 493–502
- Savastano, A., H. Klafki, U. Haußmann, T.J. Oberstein, P. Muller, O. Wirths, J. Wiltfang and T.A. Bayer, N-Truncated  $A\beta_{2-x}$  Starting with Position Two in Sporadic Alzheimer's Disease Cases and Two Alzheimer Mouse Models (1) 101–110
- Saykin, A.J., see Kim, S. (4) 991–1003
- Schatzl, H.M., see Pinnock, E.C. (3) 645–657
- Scheltens, P., see Dubois, B. (3) 617–631
- Scheltens, P., see Rosenberger, A.F.N. (4) 927–943
- Scheltens, P., see Zwan, M.D. (4) 1115–1122
- Scherrmann, J.-M., see Do, T.M. (2) 287–300
- Schiefer, I.T., see Fà, M. (3) 707–721
- Schmidtke, K., see Koppara, A. (2) 547–560
- Schott, J.M., see Clark, C.N. (1) 111–119
- Schreurs, B.G. and D.L. Sparks, Dietary High Cholesterol and Trace Metals in the Drinking Water Increase Levels of ABCA1 in the Rabbit Hippocampus and Temporal Cortex (1) 201–209
- Schröder, J., see Koppara, A. (2) 547–560
- Schroeder, C., see Leh, S.E. (1) 237–249
- Schulz, S., see Koppara, A. (2) 547–560
- Schwarz, C.G., see Madhavan, A. (3) 633–643
- Seeher, K., see Wu, H.Z.Y. (3) 755–766
- Segev, S., see Raizes, M. (3) 589–592
- Seidel, K., see Rüb, U. (4) 905–915
- Senjem, M.L., see Madhavan, A. (3) 633–643
- Seo, S.W., see Ye, B.S. (2) 483–491
- Serrano-Ríos, M., see Pastor, P. (2) 343–352
- Shah, D.J., F. Rohlfing, S. Anand, W.E. Johnson, M.T.B. Alvarez, J. Cobell, J. King, S.A. Young, J.S.K. Kauwe and S.W. Graves, Discovery and Subsequent Confirmation of Novel Serum Biomarkers Diagnosing Alzheimer's Disease (2) 317–327
- Shaik, M.A., see Chan, Q.L. (1) 121–127
- Shan, Y., D.-D. Wang, Y.-X. Xu, C. Wang, L. Cao, Y.-S. Liu and C.-Q. Zhu, Aging as a Precipitating Factor in Chronic Restraint Stress-Induced Tau Aggregation Pathology, and the Protective Effects of Rosmarinic Acid (3) 829–844
- Shang, X., see Sun, X. (1) 63–72
- Shang, X.-P., see Li, F.-D. (1) 139–147
- Shen, L.W., see Fà, M. (3) 707–721
- Shen, W., see Li, F.-D. (1) 139–147
- Shen, Y., see Shi, Z. (2) 399–405
- Shi, X., see Xie, H. (4) 961–969
- Shi, Z., Y. Zhu, M. Wang, Y. Wu, J. Cao, C. Li, Z. Xie and Y. Shen, The Utilization of Retinal Nerve Fiber Layer Thickness to Predict Cognitive Deterioration (2) 399–405
- Shibata, K., see Royall, D.R. (2) 561–570
- Shibata, K., see Royall, D.R. (2) 571–579
- Shim, Y.S., see Yoon, B. (1) 85–91
- Shin, S.A., see Yoo, Y. (2) 377–386
- Siklos, M.I., see Fà, M. (3) 707–721
- Sindic, C., see Pierrot, N. (2) 271–276
- Skoog, I., see Bjerke, M. (3) 733–741
- Slattery, C.F., see Clark, C.N. (1) 111–119
- Snaedal, J., see Einarsdottir, A.B. (1) 79–83
- Soininen, H., see Sattlecker, M. (4) 1105–1114
- Soininen, H., see Voyle, N. (3) 659–669
- Soler-Moratalla, I., see Salmerón, S. (1) 73–78
- Soricelli, A., see Lizio, R. (1) 159–177
- Sparks, D.L., see Schreurs, B.G. (1) 201–209
- Spiegel, J., E. Pirraglia, R.S. Osorio, L. Glodzic, Y. Li, W. Tsui, L.A. Saint Louis, C. Randall, T. Butler, J. Xu, R.P. Zinkowski, H. Zetterberg, J. Fortea, S. Fossati, T. Wisniewski, P. Davies, K. Blennow and M.J. de Leon, Greater Specificity for Cerebrospinal Fluid P-tau231 over P-tau181 in the Differentiation of Healthy Controls from Alzheimer's Disease (1) 93–100
- Spies, L., see Lange, C. (4) 945–959
- Springer, R.R., see Raizes, M. (3) 589–592
- Staniszewski, A., see Fà, M. (3) 707–721
- Stefánsson, E., see Einarsdottir, A.B. (1) 79–83
- Stogmann, E., D. Moser, S. Klug, A. Gleiss, E. Auff, P. Dal-Bianco, G. Pusswald and J. Lehrner, Activities of Daily Living and Depressive Symptoms in Patients with Subjective Cognitive Decline, Mild Cognitive Impairment, and Alzheimer's Disease (4) 1043–1050
- Storey, E., see Kinsella, G.J. (1) 31–43
- Strand, E.A., see Madhavan, A. (3) 633–643

- Stratmann, K., see Rüb, U. (4) 905–915
- Sun, X., R. Ma, X. Yao, X. Shang, Q. Wang, J.-Z. Wang and G. Liu, Concanavalin Agglutinin Levels are Decreased in Peripheral Blood of Alzheimer's Disease Patients (1) 63–72
- Suppa, P., see Lange, C. (4) 945–959
- Swomley, A.M., see Triplett, J.C. (1) 45–62
- Taipale, H., see Saarelainen, L. (3) 809–818
- Takeuchi, H., see Chung, J.K. (3) 743–754
- Tan, J., see Chu, D. (2) 365–375
- Tanaka, M., see Miwa, K. (2) 503–513
- Tang, G., see Xie, H. (4) 961–969
- Tang, H.-D., Y. Zhou, X. Gao, L. Liang, M.-M. Hou, Y. Qiao, J.-F. Ma and S.-D. Chen, Prevalence and Risk Factor of Cognitive Impairment were Different between Urban and Rural Population: A Community-Based Study (4) 917–925
- Taniguchi, S., see Royall, D.R. (2) 561–570
- Taniguchi, S., see Royall, D.R. (2) 571–579
- Tanskanen, A., see Saarelainen, L. (3) 809–818
- Tanskanen, M., see Mäkelä, M. (1) 149–157
- Tapadar, S., see Fà, M. (3) 707–721
- Tárraga, L., see Pastor, P. (2) 343–352
- Tavassoli, N., see Jacquin-Piques, A. (3) 671–680
- Teich, A.F., see Fà, M. (3) 707–721
- Terpstra, E., see Pan, Y. (1) 1–12
- Thalamuthu, A., see Wu, H.Z.Y. (3) 755–766
- Thatcher, G.R.J., see Fà, M. (3) 707–721
- Tiihonen, J., see Saarelainen, L. (3) 809–818
- Tischkau, S.A., see LeVault, K.R. (2) 301–316
- Tolppanen, A.-M., see Saarelainen, L. (3) 809–818
- Tong, Y., see Pan, Y. (1) 1–12
- Tosto, G., S.E. Monsell, S.E. Hawes, G. Bruno and R. Mayeux, Progression of Extrapyrarnidal Signs in Alzheimer's Disease: Clinical and Neuropathological Correlates (4) 1085–1093
- Touchon, J., see Bouc, R.L. (4) 1075–1083
- Touchon, J., see Gabelle, A. (4) 1135–1141
- Triggiani, A.I., see Lizio, R. (1) 159–177
- Triplett, J.C., A.M. Swomley, J. Cai, J.B. Klein and D.A. Butterfield, Quantitative Phosphoproteomic Analyses of the Inferior Parietal Lobule from Three Different Pathological Stages of Alzheimer's Disease (1) 45–62
- Tsai, C.-L., see Mehta, H.B. (2) 423–432
- Tsolaki, M., see Sattlecker, M. (4) 1105–1114
- Tsolaki, M., see Voyle, N. (3) 659–669
- Tsui, W., see Spiegel, J. (1) 93–100
- Tu, S., C.E. Leyton, J.R. Hodges, O. Piguet and M. Hornberger, Divergent Longitudinal Propagation of White Matter Degradation in Logopenic and Semantic Variants of Primary Progressive Aphasia (3) 853–861
- Tudor, I.C., see Novak, G. (4) 1123–1134
- Tuladhar, A.M., see van Uden, I.W.M. (3) 863–873
- Tumminelli, G., I. Di Donato, V. Guida, A. Rufa, A. De Luca and A. Federico, Oculodentodigital Dysplasia with Massive Brain Calcification and a New Mutation of GJA1 Gene (1) 27–30
- Turco, D.D., see Rüb, U. (4) 905–915
- Unverzagt, F.W., see Kim, S. (4) 991–1003
- Valentí, M., see Pastor, P. (2) 343–352
- van der Flier, W.M., see Rosenberger, A.F.N. (4) 927–943
- van der Flier, W.M., see Zwan, M.D. (4) 1115–1122
- van der Holst, H.M., see van Uden, I.W.M. (3) 863–873
- van der Vies, S.M., see Rosenberger, A.F.N. (4) 927–943
- van Dijk, E.J., see van Uden, I.W.M. (3) 863–873
- van Norden, A.G.W., see van Uden, I.W.M. (3) 863–873
- van Uden, I.W.M., H.M. van der Holst, A.M. Tuladhar, A.G.W. van Norden, K.F. de Laat, L.C.A. Rutten-Jacobs, D.G. Norris, J.A.H.R. Claassen, E.J. van Dijk, R.P.C. Kessels and F.-E. de Leeuw, White Matter and Hippocampal Volume Predict the Risk of Dementia in Patients with Cerebral Small Vessel Disease: The RUN DMC Study (3) 863–873
- Vanderstichele, H.M.J., see Barrado, L.G. (1) 187–199
- Vázquez-Higuera, J.L., see Pastor, P. (2) 343–352
- Veljanoski, R., see Zwan, M.D. (4) 1115–1122
- Vellas, B., see Jacquin-Piques, A. (3) 671–680
- Vellas, B., see Sattlecker, M. (4) 1105–1114
- Vellas, B., see Voyle, N. (3) 659–669
- Verret, L., see Bergeron, D. (3) 695–705
- Villemagne, V.L., see Zwan, M.D. (4) 1115–1122
- Volbracht, C., see Jul, P. (3) 783–795
- Voyle, N., A. Keohane, S. Newhouse, K. Lunnon, C. Johnston, H. Soininen, I. Kloszewska, P. Mecocci, M. Tsolaki, B. Vellas, S. Lovestone, on behalf of the AddNeuroMed consortium, A. Hodges, S. Kiddle and R.J.B. Dobson, A Pathway Based Classification Method for Analyzing Gene Expression for Alzheimer's Disease Diagnosis (3) 659–669
- Waern, M., see Bjerke, M. (3) 733–741
- Wagner, M., see Koppara, A. (2) 547–560
- Waldemar, G., see Nørgaard, A. (1) 211–220
- Wallack, M., see Li, H. (1) 129–137
- Wang, B., see Xie, H. (4) 961–969

- Wang, C., see Shan, Y. (3) 829–844
- Wang, D.-D., see Shan, Y. (3) 829–844
- Wang, J., see Pan, Y. (1) 1–12
- Wang, J.-Z., see Sun, X. (1) 63–72
- Wang, K., see Xie, H. (4) 961–969
- Wang, M., see Shi, Z. (2) 399–405
- Wang, Q., see Sun, X. (1) 63–72
- Wang, S., see Xie, M. (2) 353–363
- Wang, V., see Kandiah, N. (2) 277–285
- Wang, X., see Xie, M. (2) 353–363
- Wang, X.-Y., see Li, F.-D. (1) 139–147
- Wang, Y., see Pan, Y. (1) 1–12
- Wang, Y., see Xie, H. (4) 961–969
- Warren, J.D., see Clark, C.N. (1) 111–119
- Wee, H.L., see Kandiah, N. (2) 277–285
- Weekman, E.M. and D.M. Wilcock, Matrix Metalloproteinase in Blood-Brain Barrier Breakdown in Dementia (4) 893–903
- Weimar, C., see Dlugaj, M. (4) 1031–1042
- Weimar, C., see Winkler, A. (3) 797–807
- Weinger, J.G., see Liu, G. (4) 971–990
- Weiss, S.F.T., see Pinnock, E.C. (3) 645–657
- Welch, P., see Bennett, J. (4) 1179–1187
- White, L.R., see Berge, G. (2) 493–502
- Whitehouse, P.J. and D.R. George, A Tale of Two Reports: What Recent Publications from the Alzheimer's Association and Institute of Medicine say about the State of the Field (1) 21–25
- Whitwell, J.L., see Madhavan, A. (3) 633–643
- Wiendl, H., see Johnen, A. (3) 593–605
- Wilcock, D.M., see Weekman, E.M. (4) 893–903
- Williams, B., see Edwards, M. (1) 221–228
- Williams, J.B., see Nafar, F. (1) 251–263
- Williams, R., see Zwan, M.D. (4) 1115–1122
- Williams, S., see Sattlecker, M. (4) 1105–1114
- Wiltfang, J., see Koppara, A. (2) 547–560
- Wiltfang, J., see Savastano, A. (1) 101–110
- Winkler, A., C. Weimar, K.-H. Jöckel, R. Erbel, N. Dragano, M. Broecker-Preuss, S. Moebus, D. Führer-Sakel and M. Dlugaj on behalf the Heinz Nixdorf Recall Study Investigative Group, Thyroid-Stimulating Hormone and Mild Cognitive Impairment: Results of the Heinz Nixdorf Recall Study (3) 797–807
- Winkler, A., see Dlugaj, M. (4) 1031–1042
- Wirhns, O., see Savastano, A. (1) 101–110
- Wisniewski, T., see Spiegel, J. (1) 93–100
- Wolfgruber, S., see Koppara, A. (2) 547–560
- Woodward, F.J., see Clark, C.N. (1) 111–119
- Wu, H.Z.Y., K.L. Ong, K. Seeher, N.J. Armstrong, A. Thalamuthu, H. Brodaty, P. Sachdev and K. Mather, Circulating microRNAs as Biomarkers of Alzheimer's Disease: A Systematic Review (3) 755–766
- Wu, Y., see Shi, Z. (2) 399–405
- Wyman, B.T., see Novak, G. (4) 1123–1134
- Xia, L., see Geng, J. (4) 1161–1168
- Xiao, Y.-Y., see Li, F.-D. (1) 139–147
- Xie, H., C. Zhang, Y. Wang, S. Huang, W. Cui, W. Yang, L. Koski, X. Xu, Y. Li, M. Zheng, M. He, J. Fu, X. Shi, K. Wang, G. Tang, B. Wang and Y. Huo, Distinct Patterns of Cognitive Aging Modified by Education Level and Gender among Adults with Limited or No Formal Education: A Normative Study of the Mini-Mental State Examination (4) 961–969
- Xie, M., Y. Han, Q. Yu, X. Wang, S. Wang and X. Liao, UCH-L1 Inhibition Decreases the Microtubule-Binding Function of Tau Protein (2) 353–363
- Xie, S., see Chu, D. (2) 365–375
- Xie, Z., see Shi, Z. (2) 399–405
- Xu, J., see Spiegel, J. (1) 93–100
- Xu, X., see Chan, Q.L. (1) 121–127
- Xu, X., see Xie, H. (4) 961–969
- Xu, Y.-X., see Shan, Y. (3) 829–844
- Xue, F., see Liu, G. (4) 971–990
- Yagita, Y., see Miwa, K. (2) 503–513
- Yang, D. W., see Yoon, B. (1) 85–91
- Yang, W., see Xie, H. (4) 961–969
- Yao, X., see Sun, X. (1) 63–72
- Ye, B.S., E.Y. Jang, S.Y. Kim, E.-J. Kim, S.A. Park, Y. Lee, C.H. Hong, S.H. Choi, B. Yoon, S.J. Yoon, H.R. Na, J.-H. Lee, J.H. Jeong, H.J. Kim, D.L. Na and S.W. Seo, Unstable Body Mass Index and Progression to Probable Alzheimer's Disease Dementia in Patients with Amnesic Mild Cognitive Impairment (2) 483–491
- Yener, G.G., see Lizio, R. (1) 159–177
- Yin, X., see Chu, D. (2) 365–375
- Yoo, Y., S.A. Shin, S. Park, J.-H. Lee, J.-H. Youn, Y.K. Kim and J.-Y. Lee, The Korean Size/Weight Attribute Test: A Semantic Knowledge Test for Korean Older Adults and Brain-Imaging Evidence (2) 377–386
- Yoon, B., see Ye, B.S. (2) 483–491
- Yoon, B., Y.S. Shim, H.-K. Park, S.A. Park, S.H. Choi and D. W. Yang, Predictive Factors for Disease Progression in Patients With Early-Onset Alzheimer's Disease (1) 85–91
- Yoon, S.J., see Ye, B.S. (2) 483–491

Youn, J.-H., see Yoo, Y. (2) 377–386  
Young, S.A., see Shah, D.J. (2) 317–327  
Yu, C., see Liu, J. (4) 1051–1064  
Yu, L., see Han, S.D. (3) 845–851  
Yu, Q., see Xie, M. (2) 353–363  
Yuen, E., see Novak, G. (4) 1123–1134

Zetterberg, H., see Bjerke, M. (3) 733–741  
Zetterberg, H., see Spiegel, J. (1) 93–100  
Zhai, Y.-J., see Li, F.-D. (1) 139–147  
Zhang, C., see Xie, H. (4) 961–969  
Zhang, H., see Fà, M. (3) 707–721  
Zhang, X., see Liu, J. (4) 1051–1064  
Zhao, C., see Geng, J. (4) 1161–1168  
Zheng, M., see Xie, H. (4) 961–969

Zhou, Y., see Tang, H.-D. (4) 917–925  
Zhu, C.-Q., see Shan, Y. (3) 829–844  
Zhu, H., see Li, H. (1) 129–137  
Zhu, Y., see Shi, Z. (2) 399–405  
Zhuo, J., see Liu, J. (4) 1051–1064  
Zinkowski, R.P., see Spiegel, J. (1) 93–100  
Zwan, M.D., V.L. Villemagne, V. Doré, R. Buckley, P. Bourgeat, R. Veljanoski, O. Salvado, R. Williams, L. Margison, A. Rembach, S.L. Macaulay, R. Martins, D. Ames, W.M. van der Flier, K.A. Ellis, P. Scheltens, C.L. Masters and C.C. Rowe for the AIBL study, Subjective Memory Complaints in APOE  $\epsilon 4$  Carriers are Associated with High Amyloid- $\beta$  Burden (4) 1115–1122